Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

39.30 +0.46 (+1.18%)
Official Closing Price Updated: 7:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,060,193
Open 38.86
Bid (Size) 39.12 (12)
Ask (Size) 39.46 (12)
Prev. Close 38.84
Today's Range 38.86 - 39.30
52wk Range 33.67 - 45.92
Shares Outstanding 5,385,189,617
Dividend Yield 3.67%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
3 Stocks Under $10 With the Potential for Massive Gains
Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries. 
Via InvestorPlace

Performance

YTD
+4.77%
+4.77%
1 Month
-3.08%
-3.08%
3 Month
-4.70%
-4.70%
6 Month
+0.05%
+0.05%
1 Year
+9.99%
+9.99%

More News

Read More
Top Research Reports For Apple, Lowe's & Shopify
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
Via Benzinga
Exposures COVID-19
Is GSK a Top-Value Stock Right Now?
Via The Motley Fool
3 Top Cancer Treatment Stocks to Buy Now
Via InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Via MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Via InvestorPlace
Topics Economy
Exposures Economy
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
From GSK plc
Via Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
Via InvestorPlace
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
Via Benzinga
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
Via InvestorPlace
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Via Benzinga
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
Via Benzinga
Topics ETFs
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Via InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
Via Benzinga
Exposures COVID-19
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
Via The Motley Fool
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
Via Benzinga
Why Is Moderna Stock Trading Lower On Wednesday?
Via Benzinga
Exposures COVID-19
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
Via Investor's Business Daily
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Via Benzinga
UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.